

America's First Credible Anti-Mucositis Protocol – Walgreens Specialty Pharmacy Launches ProThelial™

Reducing the standard 84 day course of oral mucositis to 2-3 days or preventing it altogether, thereby averting surgical placement of feeding tubes ¹, FDA cleared ProThelial™ is the focal point the new partnership between Mueller Medical International (MMI) and Walgreens Specialty Pharmacy.

Mueller Medical, a life sciences company in Storrs Connecticut, has entered into a partnership with 193 Walgreens Specialty Pharmacies and 85 Specialty Pharmacy field's representatives, to launch a nationwide campaign against oral mucositis due to chemo-radiation. The partnership challenges the notion that there could never be a credible Anti-Mucositis Protocol of all oncology practices and bone marrow transplant units. The Phase IV post-market surveillance data on ProThelial™ gives a real-world experience of cancer treatment patients who are suffering from oral mucositis. It chronicles a different notion. The Phase IV data shows that if prescribed in a timely fashion, ProThelial™ will rapidly reduce to 2-3 days, the typical 84 day standard course of oral mucositis. Additionally, ProThelial™ can prevent it altogether. These observations are unprecedented.

The ProThelial™ is the only FDA-cleared prescription medical device containing polymerized cross-linked sucralfate. As a full management oncology support product, ProThelial™ has been associated with both the rapid reversal/elimination and complete prevention of oral mucositis. It was cleared by the FDA in August 2013, and has produced results heretofore unassociated with any mucositis intervention.

On November 8th 2014, an agreement was signed with Walgreens, wherein it will function as one of four Specialty Pharmacies to provide healthcare professionals and mucositis patients, immediate access to ProThelial™. The main goal of this partnership is to increase visibility and thereby accessibility of ProThelial™ to oncologists in the US, and to ensure that every mucositis patient has access to ProThelial™.

“We are very pleased with our new partnership with Walgreens as one of our Specialty Pharmacies for ProThelial™,” said Carleton Grose, Field Outreach Coordinator at Mueller Medical International. “We believe that every oncology facility should have a credible Anti-mucositis Protocol. ProThelial™ has demonstrated unparalleled efficacy in the prevention and reversal/elimination of mucositis and is therefore part of a credible Anti-Mucositis Protocol. We look forward to working with Walgreens in carrying this message and in getting ProThelial™ to every oncology office, and eventually into the hands of every mucositis patient. We believe that patients undergoing cancer therapy should not have to halt therapy due to mucositis. Rather mucositis may now be effectively and fully managed with ProThelial™.”

About ProThelial™

ProThelial™ is a polymerized cross-linked sucralfate paste, FDA-cleared for the management (treatment and prevention) of oral mucositis. Unlike rinses that ameliorate pain or biologic therapies that reduce the incidence of mucositis, ProThelial™ engages mucositis ulcerations with the goal of mucosal restoration and complete elimination.

About Mueller Medical International

Mueller Medical International (MMI) is a privately owned life science company focused on turning science into solutions. Founded in 1989 and currently headquartered in Storrs Connecticut USA, MMI has created products whose mechanisms of action engage mucosal physiology and produces unique, unprecedented clinical effects in diseases with few or no active therapeutic options.

For more information please visit www.prothelial.com and www.muellermedical.com

References:

1. Phase IV Post-marketing data from the ProThelial Mucositis Registry